SOUTH
SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 26,
2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the
"Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company
focused on developing novel therapies for the treatment of prostate
cancer, today announced the presentation of preclinical data for
its lead first generation androgen receptor ("AR") ANITen bAsed
Chimera ("ANITAC"™) N-terminal domain ("NTD") degrader in a poster
session at the 34th EORTC-NCI-AACR Annual Symposium on
Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
The preclinical data demonstrate that EPI-8207, an ANITAC, shows
robust potency degrading AR, including AR splice variants and
clinically relevant AR mutants that can potentially drive disease
progression in patients with castration-resistant prostate cancer
("CRPC"). In addition, EPI-8207 exhibits high potency in inhibiting
AR-dependent transcription.
Presentation Details
34th EORTC-NCI-AACR Symposium on Molecular Targets
and Cancer Therapeutics
Title: Advances in the Development of a Targeted
N-Terminal Domain Androgen Receptor Degrader (ANITAC) for the
Treatment of Prostate Cancer
Authors: Nan Hyung Hong,
et al.
Abstract Number: 103
Session Title: New Drugs
The poster is available on the EORTC-NCI-AACR Annual
Symposium website at www.eortc.org/ena and on the
"Publications" section of the Company's website at
www.essapharma.com.
About ANITAC™ Degraders
Androgen receptor signaling is the main driver of prostate
cancer progression and remains a crucial target for therapeutic
intervention in late stages of the disease. While current
antiandrogen therapies that directly or indirectly target the AR
ligand-binding domain (LBD) are initially effective, resistance
ultimately develops and new methods of inhibiting the AR pathway
are needed.
ESSA's novel approach of targeting the N-terminal domain of the
AR represents a new method of blocking AR signaling. Leveraging
ESSA's scientific foundation in successfully targeting the NTD of
the AR with a new class of small molecules called anitens, ESSA is
developing the first generation of ANITen bAsed Chimera degraders
targeting the AR NTD. In preclinical models, the orally
bioavailable ANITAC degraders can eliminate forms of AR protein
found in castration-resistant prostate cancer that can potentially
drive disease progression including LBD mutants and LBD truncated
splice variants.
About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer
among men and the fifth most common cause of male cancer death
worldwide (Globocan, 2018). Adenocarcinoma of the prostate is
dependent on androgen for tumor progression and depleting or
blocking androgen action has been a mainstay of hormonal treatment
for over six decades. Although tumors are often initially sensitive
to medical or surgical therapies that decrease levels of
testosterone, disease progression despite castrate levels of
testosterone can lead to metastatic CRPC ("mCRPC"). The treatment
of mCRPC patients has evolved rapidly over the past ten years.
Despite these advances, many patients with mCRPC fail or develop
resistance to existing treatments, leading to continued disease
progression and limited survival rates.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under @ESSAPharma.
Forward-Looking Statement
Disclaimer
This release contains certain information which, as presented,
constitutes "forward-looking information" within the meaning of the
Private Securities Litigation Reform Act of 1995 and/or applicable
Canadian securities laws. Forward-looking information involves
statements that relate to future events and often addresses
expected future business and financial performance, containing
words such as "anticipate", "believe", "plan", "estimate",
"expect", and "intend", statements that an action or event "may",
"might", "could", "should", or "will" be taken or occur, or other
similar expressions and includes, but is not limited to, statements
regarding, presentations with respect to preclinical data for the
AR ANITAC™ NTD degrader, the results of the initial preclinical
data, including the favorable pharmaceutical properties of EPI-8207
and other statements surrounding the Company's preclinical
evaluation of EPI-8207.
Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may
cause ESSA's actual results, performance or achievements to be
materially different from those expressed or implied thereby. Such
statements reflect ESSA's current views with respect to future
events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by ESSA as of the date of such statements,
are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may
make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining
positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and
economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein
and in ESSA's Quarterly Report on Form 10-Q dated August 4, 2022 under the heading "Risk Factors",
a copy of which is available on ESSA's profile on EDGAR at
www.sec.gov and on the SEDAR website at www.sedar.com, and as
otherwise disclosed from time to time on ESSA's EDGAR and SEDAR
profiles. Forward-looking statements are made based on management's
beliefs, estimates and opinions on the date that statements are
made and ESSA undertakes no obligation to update forward-looking
statements if these beliefs, estimates and opinions or other
circumstances should change, except as may be required by
applicable United States and
Canadian securities laws. Readers are cautioned against attributing
undue certainty to forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-presents-preclinical-data-for-its-first-generation-androgen-receptor-n-terminal-domain-degrader-at-the-34th-eortc-nci-aacr-symposium-301660446.html
SOURCE ESSA Pharma Inc